Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07308847 · ClinicalTrials.gov registry record · NA

Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

A NA study of Paroxysmal AF, sponsored by Medtronic Cardiac Ablation Solutions.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
9
Study locations

NCT07308847 is a NA study of Paroxysmal AF that is actively recruiting participants, run by Medtronic Cardiac Ablation Solutions. The registered enrollment target is 300 participants. The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07308847, a NA study of Paroxysmal AF, is actively recruiting participants, sponsored by Medtronic Cardiac Ablation Solutions.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
9
Study locations

Study Summary

The study is a prospective, single-arm, pre-market clinical study and will enroll up to 300 subjects at up to 26 sites in the United States (US) for analysis of primary objectives. No single site may contribute more than 15% of the enrollments.

Conditions Studied

Interventions

  • DEVICE Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System

Study Locations (9)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Southcoast Health System - Fall River

New York

  • Icahn School of Medicine at Mount Sinai - New York
  • Northwell Health Lenox Hill Hospital - New York

Arkansas

  • Arrhythmia Research Group - Jonesboro

Illinois

  • Northwestern University - Chicago

North Carolina

  • Atrium Health Wake Forest Baptist Medical Center - Winston-Salem

Ohio

  • The Ohio State University Wexner Medical Center - Columbus

Texas

  • Texas Cardiac Arrhythmia Research Foundation - Austin

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2026-01-15
Est. Completion 2027-11-22
Phase NA

What the Registry Record Tells You About NCT07308847

The ClinicalTrials.gov registry entry for NCT07308847 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Ablation Solutions, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Paroxysmal AF appearing as the primary indexed condition, and to 1 intervention - of which Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System is the first listed.

NCT07308847 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Massachusetts, New York, Arkansas.

Frequently Asked Questions

What is clinical trial NCT07308847 about?

NCT07308847 is a clinical study titled "Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)". The study is a prospective, single-arm, pre-market clinical study and will enroll up to 300 subjects at up to 26 sites in the United States (US) for analysis of primary objectives. No single site may contribute more than 15% of the enrollments.

What is the current status of trial NCT07308847?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2026-01-15. Estimated completion is 2027-11-22.

What conditions does trial NCT07308847 study?

This clinical trial studies the following conditions: Paroxysmal AF.

What interventions are being tested in trial NCT07308847?

The interventions under investigation include: Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System (DEVICE).

Who is sponsoring clinical trial NCT07308847?

This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07308847 being conducted?

This trial has 9 study locations across Arkansas, Illinois, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Paroxysmal AF

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.